Neupro approved in Japan for Parkinson’s disease and Restless Legs Syndrome

07-Jan-2013 - Japan

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Neupro® (rotigotine transdermal patch) for the treatment of Parkinson’s disease (PD) and for the symptomatic treatment of moderate-to-severe idiopathic restless legs syndrome (RLS) in adults. In 2002 Otsuka Pharmaceutical acquired the rights for developing and marketing Neupro® in Japan. UCB is responsible for development and marketing in all other regions worldwide.

Rotigotine is a once-daily transdermal patch which provides continuous delivery of the dopamine agonist over 24 hours. The Japanese approval of rotigotine is supported by randomized, controlled clinical studies in Japanese patients which have demonstrated its efficacy and safety in the treatment of PD and RLS. These studies have added to the existing data for rotigotine which has led to previous approvals in other regions such as Europe and the US.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances